Tag Archives: complement pathway

FDA Grants Orphan Status to Sanofi’s Riliprubart for Preventing and Treating Transplant Rejection

(IN BRIEF) The FDA has awarded orphan drug designation to Sanofi’s riliprubart for the treatment of antibody-mediated rejection in solid organ transplants, highlighting the therapy’s potential in an area lacking approved options. Riliprubart, a humanized IgG4 antibody targeting activated C1s … Read the full press release